Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the SNRNP200 gene.
Features include: Bone spicule pigmentation of the retina, Nyctalopia, Visual impairment, and Optic disc pallor and 3 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 4 | Visual impairment, Optic disc pallor, Attenuation of retinal blood vessels |
SNRNP200 function has not been fully characterized.
Retinitis pigmentosa 33 is associated with mutations in the SNRNP200 gene on chromosome 2.
Genetic testing for SNRNP200 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 33 has been reported in the published literature.
No clinical trials have been registered for retinitis pigmentosa 33.
80 publications have been identified in PubMed for retinitis pigmentosa 33. Research spans Epidemiology / Natural History (29%), Basic Science / Preclinical (21%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 23 | 29% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Muscles | 1 | Retinal pigment epithelial atrophy |
Laboratory research
16 |
21% |
Patient case studies | 10 | 13% |
Testing and diagnosis research | 8 | 10% |
Research summaries | 8 | 10% |
Clinical study results | 7 | 9% |
New treatment approaches | 6 | 8% |
Beaulieu C (2026). [PMID: 41954904](https://pubmed.ncbi.nlm.nih.gov/41954904/). *JAMA Ophthalmol*. [Epidemiology / Natural History]
de Guimaraes TAC (2026). [PMID: 41709431](https://pubmed.ncbi.nlm.nih.gov/41709431/). *Ophthalmic Genet*. [Epidemiology / Natural History]
Barboni M (2026). [PMID: 41691573](https://pubmed.ncbi.nlm.nih.gov/41691573/). *Doc Ophthalmol*. [Epidemiology / Natural History]
Daich Varela M (2026). [PMID: 41660487](https://pubmed.ncbi.nlm.nih.gov/41660487/). *Ophthalmol Sci*. [Epidemiology / Natural History]
Gavric AU (2026). [PMID: 42206750](https://pubmed.ncbi.nlm.nih.gov/42206750/). *Ocul Immunol Inflamm*. [Case Report / Case Series]
Josan AS (2026). [PMID: 41237986](https://pubmed.ncbi.nlm.nih.gov/41237986/). *Am J Ophthalmol*. [Clinical Trial Publication]
Most JA (2026). [PMID: 40743462](https://pubmed.ncbi.nlm.nih.gov/40743462/). *Retina*. [Basic Science / Preclinical]
Al-Moujahed A (2026). [PMID: 41891913](https://pubmed.ncbi.nlm.nih.gov/41891913/). *Ophthalmic Surg Lasers Imaging Retina*. [Epidemiology / Natural History]
Krumpoeck PE (2026). [PMID: 42020935](https://pubmed.ncbi.nlm.nih.gov/42020935/). *Ear Hear*. [Basic Science / Preclinical]
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *Am J Ophthalmol*. [Epidemiology / Natural History]